Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera
Xuping Xie(The University of Texas Medical Branch at Galveston), Yang Liu(The University of Texas Medical Branch at Galveston), Jianying Liu(The University of Texas Medical Branch at Galveston), Xianwen Zhang(The University of Texas Medical Branch at Galveston), Jing Zou(The University of Texas Medical Branch at Galveston), Camila R. Fontes-Garfias(The University of Texas Medical Branch at Galveston), Hongjie Xia(The University of Texas Medical Branch at Galveston), Kena A. Swanson(Pfizer (United States)), Mark Cutler(Pfizer (United States)), David Cooper(Pfizer (United States)), Vineet D. Menachery(The University of Texas Medical Branch at Galveston), Scott C. Weaver(The University of Texas Medical Branch at Galveston), Philip R. Dormitzer(Pfizer (United States)), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston)
Cited by 119Open Access
Abstract
We engineered three SARS-CoV-2 viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion+N501Y+D614G from UK; and E484K+N501Y+D614G from SA. Neutralization geometric mean titers (GMTs) of twenty BTN162b2 vaccine-elicited human sera against the three mutant viruses were 0.81- to 1.46-fold of the GMTs against parental virus, indicating small effects of these mutations on neutralization by sera elicited by two BNT162b2 doses.
Related Papers
No related papers found
Powered by citation graph analysis